| Literature DB >> 31775037 |
SungHee Park1, Mattia Brugiolo1, Martin Akerman2, Shipra Das3, Laura Urbanski4, Adam Geier5, Anil K Kesarwani1, Martin Fan3, Nathan Leclair4, Kuan-Ting Lin3, Leo Hu3, Ian Hua3, Joshy George6, Senthil K Muthuswamy7, Adrian R Krainer8, Olga Anczuków9.
Abstract
Misregulation of alternative splicing is a hallmark of human tumors, yet to what extent and how it contributes to malignancy are only beginning to be unraveled. Here, we define which members of the splicing factor SR and SR-like families contribute to breast cancer and uncover differences and redundancies in their targets and biological functions. We identify splicing factors frequently altered in human breast tumors and assay their oncogenic functions using breast organoid models. We demonstrate that not all splicing factors affect mammary tumorigenesis in MCF-10A cells. Specifically, the upregulation of SRSF4, SRSF6, or TRA2β disrupts acinar morphogenesis and promotes cell proliferation and invasion in MCF-10A cells. By characterizing the targets of these oncogenic splicing factors, we identify shared spliced isoforms associated with well-established cancer hallmarks. Finally, we demonstrate that TRA2β is regulated by the MYC oncogene, plays a role in metastasis maintenance in vivo, and its levels correlate with breast cancer patient survival.Entities:
Keywords: MYC; SR protein; TRA2-beta; alternative RNA splicing; breast cancer; metastasis; splicing factor; triple negative breast cancer
Mesh:
Substances:
Year: 2019 PMID: 31775037 PMCID: PMC6936330 DOI: 10.1016/j.celrep.2019.10.110
Source DB: PubMed Journal: Cell Rep Impact factor: 9.995